{"id":476770,"date":"2020-03-30T14:58:01","date_gmt":"2020-03-30T14:58:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=476770"},"modified":"2020-03-30T14:58:01","modified_gmt":"2020-03-30T14:58:01","slug":"benign-prostatic-hyperplasia-bph-epidemiology-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/benign-prostatic-hyperplasia-bph-epidemiology-forecast-to-2030_476770.html","title":{"rendered":"Benign Prostatic Hyperplasia (BPH) Epidemiology Forecast to 2030"},"content":{"rendered":"
\"Benign<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s ‘Benign prostatic hyperplasia (BPH) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Benign prostatic hyperplasia (BPH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<\/div>\n

DelveInsight<\/strong> launched its new report on Benign prostatic hyperplasia (BPH) – Epidemiology Forecast to 2030<\/a><\/p>\n

DelveInsight’s ‘Benign prostatic hyperplasia (BPH) – Epidemiology Forecast to 2030<\/strong>‘ report delivers an in-depth understanding of the disease, historical and forecasted Benign prostatic hyperplasia (BPH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

“Benign prostatic hyperplasia (BPH) refers to the proliferation of epithelial and smooth muscle cells within the transition zone of the prostate. The term has been used to describe a constellation of voiding symptoms that occur in ageing men.”<\/strong> <\/p>\n

\"\"<\/p>\n

Scope of the report:
<\/strong>1. The Benign prostatic hyperplasia (BPH) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
2. The Benign prostatic hyperplasia (BPH) Epidemiology Report and Model provide an overview of the risk factors and global trends of Benign prostatic hyperplasia (BPH) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
3. The report provides insight about the historical and forecasted patient pool of Benign prostatic hyperplasia (BPH) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
4. The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
5. The report assesses the disease risk and burden and highlights the unmet needs of Benign prostatic hyperplasia (BPH)
6. The report provides the segmentation of the Benign prostatic hyperplasia (BPH) epidemiology<\/p>\n

 Report highlights<\/strong>:
1. 11-Year Forecast of Benign prostatic hyperplasia (BPH) epidemiology
2. 7MM Coverage
3. Total Cases of Benign prostatic hyperplasia (BPH)
4. Total Cases of Benign prostatic hyperplasia (BPH) according to segmentation
5. Diagnosed cases of Benign prostatic hyperplasia (BPH)<\/p>\n

Reasons to buy:<\/strong>
1. The Benign prostatic hyperplasia (BPH) Epidemiology report will allow the user to –
2. Develop business strategies by understanding the trends shaping and driving the global Benign prostatic hyperplasia (BPH) market
3. Quantify patient populations in the global Benign prostatic hyperplasia (BPH) market to improve product design, pricing, and launch plans
4. Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Benign prostatic hyperplasia (BPH) therapeutics in each of the markets covered
5. Understand the magnitude of Benign prostatic hyperplasia (BPH) population by its epidemiology
6. The Benign prostatic hyperplasia (BPH) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources<\/p>\n

Related reports:<\/strong><\/p>\n

Benign prostatic hyperplasia (BPH) – Market Insights, Epidemiology, and Market Forecast-2030<\/a><\/p>\n

Benign prostatic hyperplasia (BPH) Pipeline Insight, 2020<\/a><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight’s ‘Benign prostatic hyperplasia (BPH) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Benign prostatic hyperplasia (BPH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-476770","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=476770"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476770\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=476770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=476770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=476770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}